OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 436 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas June 27, 2023 How can we improve LGBTQ+ cancer care? – That Cancer Conversation June 27, 2023 To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... February 18, 2021 How can we improve LGBTQ+ cancer care? – That Cancer Conversation... June 27, 2023 Load more HOT NEWS Political Interests Are A Major Adversary in the War on Women The new home for your research tools How to Get Started With Exercising at Home During Cancer HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in...
